UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  ------------

                                    FORM 6-K

                                  ------------

                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934


                                 March 30, 2010


                                  ------------

                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)


                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                                     DENMARK
                    (Address of principal executive offices)

                                  ------------

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]


Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________



                                 TRANSLATION OF:

                   ARTICLES OF ASSOCIATION OF NOVO NORDISK A/S

1.   NAME

1.1  The Company's name is Novo Nordisk A/S.

1.2  The Company also carries on business under the secondary names:
     -    Novo Industri A/S
     -    Novo Terapeutisk Laboratorium A/S
     -    Nordisk Gentofte A/S
     -    Nordisk Insulinlaboratorium A/S

2.   REGISTERED OFFICE

2.1  The  Company's  registered  office  is  situated  in  the  municipality  of
     Gladsaxe.

3.   OBJECTS

3.1  The  Company's  objects are to carry out  research and  development  and to
     manufacture  and  commercialise   pharmaceutical,   medical  and  technical
     products  and  services as well as any other  activity  related  thereto as
     determined  by the Board of Directors.  The Company  strives to conduct its
     activities in a financially, environmentally, and socially responsible way.

4.   SHARE CAPITAL

4.1  The Company's share capital amounts to DKK 620,000,000 divided into A share
     capital of DKK 107,487,200 and B share capital of DKK 512,512,800.

4.2  The share capital is divided into shares of DKK 0.01 or multiples thereof.

4.3  The share capital has been fully paid up.


5.   SHARES AND REGISTER OF OWNERS

5.1  The A shares  shall be  issued  in the  names of the  holders  and shall be
     entered in the holders'  names in the Company's  Register of Owners.  Share
     certificates  may be issued for the A shares.  The B shares shall be issued
     through a central securities  depository as well as to bearer, and they may
     be  registered  in the names of the  holders in the  Company's  Register of
     Owners  upon  request.  Entry of a B share under the  holder's  name in the
     Company's  Register of Owners  shall be subject to the  condition  that the
     Company  has  been  notified  of  such  entry  by  the  central  securities
     depository.  The  Company  shall  not be  liable  for  the  correctness  of
     notifications received from the central securities depository.

5.2  The A shares  shall be  non-negotiable  instruments.  The B shares shall be
     negotiable instruments.

5.3  In addition,  the Articles of Association  contain  special rules as to the
     pre-emptive  subscription  rights of  holders  of A shares  and B shares in
     connection with an increase of the share capital (Articles 6.1 and 6.2), as
     to the  transferability  of A shares (Articles  5.4-5.7),  as to the voting
     rights  carried by A shares and B shares  (Articles 9.3 and 9.4), as to the
     dividend  rights  of A  shares  and B  shares  (Article  18)  and as to the
     preferential  rights  of B  shares  to be  covered  in case of  winding  up
     (Article 19.2). In other respects, no shares shall carry special rights.

5.4  Where a shareholder  wants to sell one or more A shares,  such shares shall
     be offered to the Board of  Directors  on behalf of the other  holders of A
     shares at a price not lower than the average of the buying price quoted for
     the B shares on NASDAQ OMX Copenhagen during the last three months prior to
     the  submission  of  such  offer.  The  offer  shall  be  accompanied  by a
     certificate  issued by a bank proving the stated  average  price.  Where no
     price has been quoted for the B shares  during the last three  months prior
     to the submission of such offer,  the A shares intended to be sold shall be
     offered at a price not lower than the value  assessed for the B shares by a
     bank  selected  by the Board of  Directors.  Such  assessment  shall be the
     average  of the  prices  estimated  by such bank for each of the last three
     months prior to the submission of such offer.  Within 30 days of receipt of
     such offer,  the Board of Directors  shall inform the  shareholder  whether
     other holders of A shares wish to acquire the shareholding in question. The
     purchase  price  shall be paid no later than two  months  after it has been
     fixed.

5.5  If the other holders of A shares do not exercise or do not fully



     exercise their preferential right to acquire the A shares offered, then the
     shareholder  intending to sell shall be entitled - within a period of three
     months - to sell any  shares  that  have not  been  acquired  by the  other
     shareholders  to any third party on the same terms and  conditions as those
     contained in the offer  submitted  to the Board of  Directors  according to
     Article 5.4 above.

5.6  Articles  5.4  and 5.5  shall  not  apply  to any  transfer  of  shares  by
     inheritance or to a shareholder's transfer of shares during his lifetime to
     his spouse, issue, or to family foundations.

5.7  Articles 5.4 and 5.5 shall moreover apply to compulsory sales in connection
     with  administration of estates or to proceedings or any other action taken
     by creditors.

5.8  No restrictions shall apply to the transferability of B shares.

5.9  No shareholder  shall be obliged to have his shares redeemed in whole or in
     part.

5.10 Shares which have not been issued through a central  securities  depository
     and coupon  sheets  pertaining to such shares may be cancelled by the Board
     of  Directors  without  any  order of the  court  pursuant  to the rules on
     cancellation contained in applicable law in force from time to time.

6.   INCREASE OF THE SHARE CAPITAL

6.1  In case the share capital is increased by issuance of A shares as well as B
     shares,  the existing  ratio  between the two classes of shares must not be
     changed.  In case of such an  increase,  holders  of A shares  shall have a
     pre-emptive  right to subscribe  for new A shares,  and holders of B shares
     shall have a pre-emptive right to subscribe for new B shares.

6.2  Where the share  capital is increased  by either A shares or B shares,  the
     holders of both  classes  of shares  shall  have  proportionate  preemptive
     subscription rights for the new A shares or the new B shares respectively.

6.3  Until 12 March 2013, the Board of Directors  shall be  authorised,  without
     granting any pre-emptive rights to the shareholders,  to increase the share
     capital in one or more stages by issuing B shares of up to a total  nominal
     value of DKK  3,000,000  and to offer those shares to the  employees of the
     Company or its subsidiaries at a price which is lower than the market price
     of the B shares.

6.4  Furthermore,  until  12  March  2013,  the  Board  of  Directors  shall  be
     authorised  to increase the share  capital in one or more stages by up to a
     total nominal value of DKK 107,000,000.  A capital increase may be effected
     by cash payment or by contribution of assets other than


     cash.

     If the capital  increase is effected by cash  payment and the  subscription
     price equals the market  price,  the Board of Directors may decide that the
     capital  increase  shall be  effected  by the  issue  of B shares  only and
     without any pre-emptive subscription rights for the existing shareholders.

     If the capital  increase is effected by cash  payment and the  subscription
     price is  lower  than the  market  price,  the  capital  increase  shall be
     distributed   proportionally  between  A  shares  and  B  shares  and  with
     pre-emptive subscription rights for the existing shareholders.

     If the capital  increase is effected by  contribution  of assets other than
     cash, then the new shares shall be B shares,  which shall be issued without
     pre-emptive subscription rights for the existing shareholders.

6.5  The following shall apply to any increase of the share capital  pursuant to
     Articles  6.3-6.4:  (i) A shares  shall be  registered  in the names of the
     holders,  whereas B shares shall be issued to bearer,  although they may be
     registered in the names of the holders in the Company's Register of Owners,
     (ii) A shares shall be non-negotiable instruments whereas B shares shall be
     negotiable instruments, (iii) the provisions of the Articles of Association
     relating to A shares and/or B shares, respectively, hereunder regarding the
     preferential  rights in Articles  5.4-5.7 and the pre-emptive  subscription
     rights in 6.1-6.2  shall in addition  be  applicable  to shares  within the
     respective classes of shares.

7.   LOCATION, TIME AND CONVENING OF GENERAL MEETINGS

7.1  The  Company  in  General  Meeting  shall,  subject  to Danish  law and the
     limitations set out in the Articles of  Association,  exercise the ultimate
     authority over the Company.

7.2  General Meetings shall be held at a venue in the Capital Region of Denmark.

7.3  The Annual  General  Meeting shall be held before the end of April in every
     year.

7.4  Extraordinary  General Meetings shall be held as resolved by the Company in
     General  Meeting  or the Board of  Directors,  or upon the  request  of the
     auditor(s) or shareholders representing in total at least 1/20 of the share
     capital.  Such  request  shall be  submitted  in  writing  to the  Board of
     Directors and be accompanied  by specific  proposals for the business to be
     transacted.  The  Extraordinary  General  Meeting  shall then be called not
     later than two weeks after such request has been made.

7.5  A General Meeting shall be called by the Board of Directors at not



     more than five weeks and not later than three  weeks  prior to the  General
     Meeting.  The  notice  calling  such  Meeting  shall be  advertised  in two
     national  daily  newspapers as  determined  by the Board of Directors.  The
     notice  convening  the Meeting  shall also be  forwarded  in writing to all
     shareholders entered in the Register of Owners who have so requested and be
     advertised in the IT system of the Danish Commerce and Companies Agency. At
     the same time the notice  convening  the Meeting  shall be published at the
     Company's website: novonordisk.com.

7.6  For a period  of three  weeks  prior to the  General  Meeting  up until and
     including the day of the General  Meeting,  a copy of the notice  convening
     the Meeting  with  agenda,  the  complete  proposals,  the  documents to be
     presented  at the General  Meeting,  information  about  voting and capital
     structure at the time of  convening  the Meeting as well as forms for issue
     of proxy and voting by  correspondence  shall be available at the Company's
     website: novonordisk.com.

8.   AGENDA, CHAIRMAN AND MINUTES OF GENERAL MEETINGS

8.1  Any shareholder shall be entitled to have a specific subject  considered by
     the Company in Annual General  Meeting.  The Company shall receive proposal
     to this effect not later than six weeks prior to the  General  Meeting.  If
     the Company receives the proposal later than six weeks prior to the General
     Meeting, the Board of Directors may decide,  however, that the proposal has
     been submitted in time for the subject to be included on the agenda anyway.

8.2  The agenda of the Annual General Meeting shall include the following:

     1.   The Board of Directors' oral report on the Company's activities in the
          past financial year.

     2.   Presentation and adoption of the audited Annual Report.

     3.   Approval of the remuneration of the Board of Directors.

     4.   A resolution to distribute  the profit or cover the loss  according to
          the adopted Annual Report.

     5.   Election of members to the Board of Directors,  including chairman and
          vice chairman.

     6.   Appointment of auditor(s).

     7.   Any proposals from the Board of Directors and/or shareholders.

     8.   Any other business.

8.3  General  Meetings  shall be presided  over by a chairman,  appointed by the
     Board of Directors. The chairman shall decide on all matters



     relating to the business  transacted,  the casting of votes and the results
     of voting.

8.4  The  business  transacted  at the  General  Meeting  shall be recorded in a
     minute book to be signed by the chairman.

8.5  The Board of Directors  may decide that a General  Meeting shall be held in
     English.  All documents  prepared for the purpose of the General Meeting in
     connection  with or after the General  Meeting  shall be in both Danish and
     English. The Board of Directors shall ensure that simultaneous  translation
     to and from Danish shall be available for all attendees.

9.   RIGHT OF ATTENDANCE AND VOTING RIGHTS AT GENERAL MEETINGS

9.1  A  shareholder's  right to attend  and vote at a General  Meeting  shall be
     determined  by the shares which such  shareholder  owns at the record date.
     The record date shall be one week prior to the General Meeting.  The shares
     held by each  shareholder  at the record date shall be calculated  based on
     the registration of the  shareholder's  shares in the Register of Owners as
     well  as  any  notification   received  by  the  Company  with  respect  to
     registration  of shares in the Register of Owners,  which have not yet been
     entered in the Register of Owners.

9.2  Any shareholder who is entitled to attend the General Meeting,  cf. Article
     9.1,  and who  wants to  attend  the  General  Meeting  shall  apply for an
     admission  card to such General  Meeting not later than three days prior to
     the holding of the  Meeting.  Unless the  shareholder  states an address to
     which  the  admission  card is to be  sent,  the  admission  card  shall be
     collected  at the  Company's  offices  not later  than the day  before  the
     General Meeting.

9.3  Each class A share capital amount of DKK 0.01 shall carry 10 votes.

9.4  Each class B share capital amount of DKK 0.01 shall carry 1 vote

9.5  The voting  right may be exercised by a  proxy-holder,  provided,  however,
     that such holder substantiates  his/her right to attend the General Meeting
     by  presenting  an admission  card and a duly dated  written  instrument of
     proxy.  Shareholders  who are  entitled  to attend a General  Meeting,  cf.
     Article  9.1,  may also  vote by  correspondence.  Such  votes  shall be in
     writing  and be received by the Company not later than the day prior to the
     General Meeting.

10.  RESOLUTIONS AT GENERAL MEETINGS, MAJORITY OF VOTES AND QUORUM

10.1 Resolutions by the General  Meeting shall be passed by a simple majority of
     votes, unless stricter requirements are made under the



     Danish Companies Act or the Articles of Association.


10.2 Any resolution to amend the Articles of Association, which under Danish law
     shall be passed by the General Meeting,  shall be subject to adoption by at
     least 2/3 of the votes  cast and of the share  capital  represented  at the
     General  Meeting,  unless  other  requirements  as to the adoption are made
     under the Danish Companies Act.

10.3 Any resolution to amend the Articles of Association, which under Danish law
     shall be passed by the  General  Meeting  by at least 2/3 of the votes cast
     and of the share capital  represented at the General Meeting or by a higher
     majority of votes, shall only be passed at one General Meeting, if at least
     2/3 of the total number of votes in the Company has been represented at the
     General Meeting ("the quorum requirement").

10.4 If the quorum  requirement is not fulfilled,  the Board of Directors  shall
     within two weeks convene  another  General  Meeting at which the resolution
     may be passed in accordance  with Article 10.2  irrespective  of the quorum
     requirement.

10.5 Any  proxy  to  attend  and  vote  at  the  first  General  Meeting  shall,
     notwithstanding  Article 9.5 and unless  expressly  revoked,  be considered
     valid  also in respect of the second  General  Meeting,  provided  that the
     requirements  concerning exercise of voting right, cf. Article 9.1 and 9.2,
     are fulfilled at the second General Meeting.

11.  BOARD OF DIRECTORS

11.1 The Board of Directors shall be in charge of managing the Company.

11.2 The Board of  Directors  shall  consist  of 4 to 10  members,  including  a
     chairman  and a vice  chairman,  to be  elected  by the  Company in General
     Meeting.  The General  Meeting  shall elect  directly the chairman and vice
     chairman.  Each member  shall hold office for one year at a time.  Retiring
     members may be re-elected.

11.3 The Board of Directors  shall moreover  include a number of members elected
     by the employees of the Company and its  subsidiaries  in  accordance  with
     applicable law thereon in force from time to time.

11.4 The vice chairman shall act as substitute for the chairman. In the event of
     permanent  absence  of the  chairman  and/or  vice  chairman,  the Board of
     Directors  shall be entitled to elect a new  chairman or vice  chairman who
     shall remain in office until the next Annual General Meeting.

11.5 Board Meetings  shall be convened and presided over by the Chairman.  Board
     Meetings  shall be  convened  if so  requested  by a member of the Board of
     Directors or by a member of the Management or auditor  registered  with the
     Commerce and Companies Agency.



11.6 The Board of Directors shall constitute a quorum when more than half of its
     members are present.

11.7 For the  Board  of  Directors  to pass a  resolution,  the vote of a simple
     majority of the members present is required.  In case of a parity of votes,
     the chairman shall hold the casting vote.

11.8 The Board of Directors  shall lay down its own rules of  procedure  for the
     performance of its duties and exercise of its powers.

11.9 The business  transacted at the Meetings of the Board of Directors shall be
     recorded  in a minute  book to be  signed  by all  members  of the Board of
     Directors.

11.10 The members of the Board of Directors shall receive an annual fee which is
     subject to approval by the General Meeting

12.  MANAGEMENT

12.1 The Board of Directors shall appoint a managing director  (President) to be
     in  charge  of the  day-to-day  management  of the  Company.  The  Board of
     Directors may also appoint up to eight additional  managers (Executive Vice
     Presidents).  All  managers  shall  be  registered  with the  Commerce  and
     Companies Agency.

13.  LANGUAGE

13.1 The Company's corporate language is English.

14.  POWERS TO BIND THE COMPANY

14.1 The  Company  shall be  legally  bound (i) by the joint  signatures  of two
     members of the Executive  Management or (ii) by the joint signatures of one
     such  member  of the  Executive  Management  or a  member  of the  Board of
     Directors  and the  chairman or vice  chairman of the Board of Directors or
     (iii) by the joint signatures of all members of the Board of Directors.

15.  GUIDELINES FOR INCENTIVE-BASED REMUNERATION

15.1 The Company has laid down guidelines for  incentive-based  remuneration for
     the Board of Directors and Executive Management. The guidelines, which have
     been  adopted  by the  Company's  general  meeting,  are  available  at the
     Company's website: novonordisk.com.



16.        AUDITING

16.1 The audit shall be carried out by one  state-authorised  public accountant,
     unless more auditors are required under the law.


16.2 The  auditor  shall  be  appointed  by  the  Annual  General  Meeting.  The
     appointment  shall be for a term of one year.  The retiring  auditor may be
     reappointed. An auditing company may be appointed auditor.

17.  FINANCIAL YEAR AND ANNUAL REPORT

17.1 The financial year of the Company shall be the calendar year.

17.2 The Annual Report shall be presented in conformity  with the rules in force
     from time to time.

18.  DISTRIBUTION OF DIVIDEND

18.1 Any profit  according  to the adopted  Annual  Report shall first of all be
     transferred to the necessary reserves. Dividend shall be distributed with a
     priority dividend of 1/2% to the holders of A shares and then, in priority,
     up to a dividend  of 5% to the  holders of B shares.  Any  distribution  of
     additional  dividends shall be subject to the provision that the holders of
     A shares shall never receive a total dividend exceeding the percentage rate
     of the dividend paid to the holders of B shares.

18.2 Dividends  on A  shares  shall  be  remitted  to  the  shareholders  at the
     addresses entered in the Company's Register of Owners as at the date of the
     Annual  General  Meeting.  Dividends  on B shares  shall be paid with fully
     discharging effect for the Company through a central securities  depository
     and an  account-holding  bank to  shareholders  registered  by the  central
     securities depository at the time of payment.

19.  DISSOLUTION

19.1 Unless otherwise provided by Danish law, any resolution for the dissolution
     of the  Company  shall be passed  by the  Company  in  General  Meeting  in
     accordance  with  the  provisions  on  the  amendment  of the  Articles  of
     Association  (Articles  10.2-10.4).  Where a  resolution  to  dissolve  the
     Company is passed,  such dissolution shall be effected by voluntary winding
     up proceedings.

19.2 When  distributing the proceeds of the winding up proceedings,  the B share
     capital shall be covered in priority at its nominal value,  following which
     the A share capital  shall be covered in the same manner.  The holders of A
     and B shares shall subsequently rank equally in proportion to their nominal
     holdings in respect of further distributions.



These Articles of Association were adopted on 24 March 2010.


                            Chairman of the Meeting:




                             ______________________
                                 Klaus S0gaard



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.

Date: March 30, 2010                           NOVO NORDISK A/S
                             ---------------------------------------------------
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer